Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein

Annals of Pharmacotherapy

Volumn 39, Issue 3, 2005, Pages 523-526

  Backes, James M ^a,c   Gibson, Cheryl A ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Fibrates; Low density lipoprotein; Niacin; Small dense; Statins

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; SMALL DENSE LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ATHEROGENESIS; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; PRIORITY JOURNAL; REVIEW; SLOW DRUG RELEASE; SUSTAINED RELEASE PREPARATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; CLOFIBRIC ACID; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; NIACIN; RANDOMIZED CONTROLLED TRIALS;

EID: 13944253199     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E322     Document Type: Review

References (25)

1. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 1997;95:69-75.
2. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994;106:241-53.
3. Watts GF, Mandalia S, Brunt JN, Slavin BM, Coltart DJ, Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism 1993;42:1461-7.
4. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001;285:2486-97.
5. Chapman M, Guerin M, Brucken E. Atherogenic, dense low-density lipoproteins: pathophysiology and new therapeutic approaches. Eur Heart J 1998;19:A24-A30.
6. Grundy S. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997;95:1-4.
7. Hirano T, Yoshino G, Kashiwazaki K, Adachi M. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients, Am J Hypertens 2001;14:908-13.
8. Tack CJ, Smits P, Demacker PN, Stalenhoef AF. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998;21:796-9.
9. Calabresi L, Donati D, Pazzucconi F, Sirtori C, Franceschini G. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis 2000;148:387-96.
10. Zambon S, Cortella A, Sartore G, Baldo-Enzi G, Mansato E, Crepaldi G. Pravastatin treatment in combined hyperlipidemia: effect on plasma lipoprotein levels and size. Eur J Clin Pharmacol 1994;46:221-4.
11. Superko H, Krauss R, DiRicco C. Effect of fluvastatin on low-density lipoprotein peak particle diameter. Am J Cardiol 1997;80:78-81.
12. Forster L, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, et al. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 2002;164:129-45.
13. Guerin M, Lassel T, LeGoff W, Farnier M, Chapman M. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000;20:189-210.
14. Guerin M, Egger P, Soudant C, Le Goff W, Tol A, Dupuis R, et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 2002;163:287-96.
15. März W, Scharnagl H, Abletshauser C, Hoffmann MM, Berg A, Keul J, et al. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation 2001;103:1942-8.
16. Winkler K, Abletshauser C, Hoffmann MM, Friedrich I, Baumstark MW, Wieland H, et al. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab 2002;87:5485-90.
17. McKenney J, McCormick L, Schaefer E, Black D, Watkins M. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 2001;88:270-4.
18. Morgan J, Capuzzi D, Baksh R, Intenzo C, Carey CM, Reese D, et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 2003;91:1432-6.
19. Superko H, on behalf of the KOS Investigators. Effect of nicotinic acid on LDL subclass patterns (abstract). Circulation 1994;90:I-504.
20. Superko H, Krauss R. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 1992;95:69-76.
21. Brown B, Zambon A, Poulin D, Rocha A, Maher V, Davis JW, et al. Use of niacin, statins, and resins in patients with combined hyperlipidemia. Am J Cardiol 1998;81:52B-59B.
22. Yuan J, Tsai M, Hunninghake D. Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 1994;110: 1-11.
23. Tsai M, Yuan J, Hunninghake D. Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies. Atherosclerosis 1992; 95:35-42.
24. Lemieux I, Laperriere L, Dzavik V, Tremblay G, Bourgeois J, Despres J. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis 2002;162:363-71.
25. Frost R, Otto C, Geiss H, Schwandt P, Parhofer K. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 2001;87:44-8.